KMT2A and acute myeloid leukemia: GA was more frequent in NPM1wt AML compared to the NPM1mut AML cohort and included ASXL1 (17.1% vs. 3.6%; p < 0.0001), BCOR (7.5% vs. 1.6%; p < 0.0001), KMT2A (14.7% vs. 0.2%; p < 0.0001), RUNX1 (22.5% vs. 1.9%; p < 0.0001), STAG2 (6.9% vs. 1.6%; p < 0.0001), TP53 (19.1% vs. 4.1%; p < 0.0001), SRSF2 (12.3% vs. 9.8%; ns), U2AF1 (6.8% vs. 1.3%; p < 0.0001), and KRAS (9.3% vs. 7.0%; p = 0.07).